CSF3 and breast carcinoma: Another bispecific antibody MDX-210 co-targeting HER2/neu and FcγRI increased the efficacy in vitro when combined with granulocyte-colony stimulating factor (G-CSF) in breast cancer patients overexpressing HER2/neu [89].